Plus Therapeutics Inc (PSTV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Plus Therapeutics Inc (PSTV) has a cash flow conversion efficiency ratio of -1.566x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.26 Million) by net assets ($4.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Plus Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Plus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Plus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Plus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Plus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kim Hin Industry Bhd
KLSE:5371
|
-0.008x |
|
Lumens Co. Ltd
KQ:038060
|
0.074x |
|
Taya Inv-L
TA:TAYA
|
-0.004x |
|
Astoria Investments Ltd
JSE:ARA
|
-0.008x |
|
AVTECH Sweden AB Series B
ST:AVT-B
|
0.012x |
|
Varengold Bank AG
F:VG8
|
N/A |
|
Advanced Braking Technology Ltd
AU:ABV
|
0.134x |
|
Latch Inc
NASDAQ:LTCH
|
-0.134x |
Annual Cash Flow Conversion Efficiency for Plus Therapeutics Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Plus Therapeutics Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see PSTV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.00 Million | $-20.77 Million | -5.199x | -540.83% |
| 2024-12-31 | $-8.95 Million | $-10.55 Million | 1.179x | -87.63% |
| 2023-12-31 | $-1.35 Million | $-12.85 Million | 9.533x | +573.66% |
| 2022-12-31 | $6.45 Million | $-12.97 Million | -2.013x | -112.16% |
| 2021-12-31 | $10.84 Million | $-10.28 Million | -0.949x | +65.91% |
| 2020-12-31 | $3.03 Million | $-8.43 Million | -2.783x | +45.35% |
| 2019-12-31 | $1.16 Million | $-5.91 Million | -5.091x | -122.15% |
| 2018-12-31 | $5.22 Million | $-11.97 Million | -2.292x | -64.35% |
| 2017-12-31 | $13.00 Million | $-18.13 Million | -1.394x | +21.57% |
| 2016-12-31 | $10.99 Million | $-19.53 Million | -1.778x | -6.03% |
| 2015-12-31 | $12.21 Million | $-20.47 Million | -1.677x | -131.53% |
| 2014-12-31 | $-5.70 Million | $-30.33 Million | 5.319x | +148.20% |
| 2013-12-31 | $3.13 Million | $-34.56 Million | -11.035x | -121.27% |
| 2012-12-31 | $6.46 Million | $-32.19 Million | -4.987x | -40.43% |
| 2011-12-31 | $9.95 Million | $-35.32 Million | -3.551x | -244.59% |
| 2010-12-31 | $22.87 Million | $-23.57 Million | -1.031x | -115.84% |
| 2009-12-31 | $-3.66 Million | $-23.81 Million | 6.508x | +50.42% |
| 2008-12-31 | $-7.72 Million | $-33.39 Million | 4.327x | +35.59% |
| 2007-12-31 | $-9.40 Million | $-30.00 Million | 3.191x | +109.33% |
| 2006-12-31 | $-10.81 Million | $-16.48 Million | 1.524x | +762.42% |
| 2005-12-31 | $-6.23 Million | $-1.10 Million | 0.177x | +118.04% |
| 2004-12-31 | $12.83 Million | $-12.57 Million | -0.980x | -101.63% |
| 2003-12-31 | $14.91 Million | $-7.25 Million | -0.486x | -83.45% |
| 2002-12-31 | $26.00 Million | $-6.89 Million | -0.265x | -22.50% |
| 2001-12-31 | $38.49 Million | $-8.32 Million | -0.216x | -257.74% |
| 2000-12-31 | $49.34 Million | $-2.98 Million | -0.060x | -107.28% |
| 1999-12-31 | $-6.15 Million | $-5.11 Million | 0.831x | +105.89% |
| 1998-12-31 | $108.00K | $-1.52 Million | -14.102x | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more